← Leaderboards
Rudolph Juliano
University Of North Carolina Chapel Hill
$14,527,279
Attributed
$14,765,944
Total exposure
17
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.3M · FY2005–21$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$44,816,091 · 19
By mechanism
U54$21,030,495 · 3
P01$15,680,147 · 4
R01$5,207,851 · 6
R44$1,726,954 · 1
R41$536,962 · 2
R21$320,682 · 1
Top collaborators
- Stephen Vernon Frye1 shared
- William Perry Janzen1 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- C. William Davis$5,308,583
- Rihe Liu$10,529,623
- David B Peden$24,843,616
- Richard C Boucher$55,332,929
- Alan K Howe$7,548,597
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsGene ExpressionOligonucleotidesTissuesIntegrinsBaseDesignComplexCytosolProteinsCell Growth RegulationTechnologyIn VivoEvaluationTranscription FactorUptakeLigandsDrug KineticsMolecularBiological Signal TransductionApoptosisProgramsPeptidesPharmacodynamics
Grant awards (68)
Therapy of Pulmonary Diseases with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds$888,678
R44 · FY2021 · TR · contact PI
Therapy of Pulmonary Diseases with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds$838,276
R44 · FY2020 · TR · contact PI
Correction of Splicing Defects in Cystic Fibrosis with Peptide-Oligonucleotide Conjugates and Small Molecule Enhancing Compounds$224,931
R41 · FY2019 · TR · contact PI
Development of Small Molecules that Enhance the Delivery and the Pharmacological Effects of Oligonucleotides$312,031
R41 · FY2015 · TR · contact PI
Intracellular Trafficking of Antisense and siRNA Oligonucleotides in Cancer Cells$297,887
R01 · FY2014 · CA · contact PI
Intracellular Trafficking of Antisense and siRNA Oligonucleotides in Cancer Cells$288,674
R01 · FY2013 · CA · contact PI
Addressing Undruggable Targets Using Oligonucleotides and Small Molecules (PQ18)$155,382
R21 · FY2013 · CA · contact PI
Intracellular Trafficking of Antisense and siRNA Oligonucleotides in Cancer Cells$307,100
R01 · FY2012 · CA · contact PI
Addressing Undruggable Targets Using Oligonucleotides and Small Molecules (PQ18)$165,300
R21 · FY2012 · CA · contact PI
Intracellular Trafficking of Antisense and siRNA Oligonucleotides in Cancer Cells$307,100
R01 · FY2011 · CA · contact PI
The Pharmacodynamics of Genes and Oligonucleotides$56,453
P01 · FY2010 · GM · contact PI
Carolina Center of Cancer Nanotechnology Excellence$3,507,500
U54 · FY2009 · CA · contact PI
The Pharmacodynamics of Genes and Oligonucleotides$1,293,268
P01 · FY2009 · GM · contact PI
Carolina Center of Cancer Nanotechnology Excellence$650,000
U54 · FY2009 · CA · contact PI
Nanopatterned Surfaces for the Analysis of Tumor Cell Signaling and Migration$587,840
U54 · FY2009 · CA · contact PI
DRUG DELIVERY CPPs$521,444
P01 · FY2009 · GM · contact PI
Enhanced Delivery of Protein Biosensors: a Combinatorial Library Strategy$343,100
R01 · FY2009 · GM · contact PI
Carolina Center of Cancer Nanotechnology Excellence$46,141
U54 · FY2009 · CA · contact PI
Carolina Center of Cancer Nanotechnology Excellence$46,141
U54 · FY2009 · CA · contact PI
The Pharmacodynamics of Genes and Oligonucleotides$39,762
P01 · FY2009 · GM · contact PI
Carolina Center of Cancer Nanotechnology Excellence$3,430,039
U54 · FY2008 · CA · contact PI
The Pharmacodynamics of Genes and Oligonucleotides$1,255,598
P01 · FY2008 · GM · contact PI
Nanopatterned Surfaces for the Analysis of Tumor Cell Signaling and Migration$557,491
U54 · FY2008 · CA · contact PI
DRUG DELIVERY CPPs$491,154
P01 · FY2008 · GM · contact PI
Enhanced Delivery of Protein Biosensors: a Combinatorial Library Strategy$343,100
R01 · FY2008 · GM · contact PI
Carolina Center of Cancer Nanotechnology Excellence$3,373,755
U54 · FY2007 · CA · contact PI
The Pharmacodynamics of Genes and Oligonucleotides$1,292,931
P01 · FY2007 · GM · contact PI
Nanopatterned Surfaces for the Analysis of Tumor Cell Signaling and Migration$546,539
U54 · FY2007 · CA · contact PI
DRUG DELIVERY CPPs$505,759
P01 · FY2007 · GM · contact PI
Enhanced Delivery of Protein Biosensors: a Combinatorial Library Strategy$343,100
R01 · FY2007 · GM · contact PI
INTEGRIN SIGNALING IN THE VASCULAR SYSTEM$331,293
P01 · FY2007 · HL · contact PI
Carolina Center of Cancer Nanotechnology Excellence$3,378,695
U54 · FY2006 · CA · contact PI
The Pharmacodynamics of Genes and Oligonucleotides$1,475,639
P01 · FY2006 · GM · contact PI
Nanopatterned Surfaces for the Analysis of Tumor Cell Signaling and Migration$387,062
U54 · FY2006 · CA · contact PI
INTEGRIN SIGNALING IN THE VASCULAR SYSTEM$314,770
P01 · FY2006 · HL · contact PI
DRUG DELIVERY CPPs$240,432
P01 · FY2006 · GM · contact PI
Major Challenges in Clinical Medicine: An Overview for *$150,000
R13 · FY2006 · DK · contact PI
Carolina Center of Cancer Nanotechnology Excellence$3,899,965
U54 · FY2005 · CA
The Pharmacodynamics of Genes and Oligonucleotides$1,569,016
P01 · FY2005 · GM
Nanopatterned Surfaces for the Analysis of Tumor Cell Signaling and Migration$483,347
U54 · FY2005 · CA
Integrin Signaling in the Vascular Systems$314,721
P01 · FY2005 · HL
Targeting Cancer Cell DNA with Combinatorial Ligands$271,120
R01 · FY2005 · CA
DRUG DELIVERY CPPs$233,428
P01 · FY2005 · GM
Oligo/Admin Cores$221,518
P01 · FY2005 · GM
Challenges Clinical Medicine:Overview for Scientist(RMI)$150,000
R13 · FY2005 · DK
Administrative Core$135,980
U54 · FY2005 · CA
THE PHARMACODYNAMICS OF GENES AND OLIGONUCLEOTIDES$962,793
P01 · FY2004 · GM
Integrin Signaling in the Vascular Systems$307,248
P01 · FY2004 · HL
Targeting Cancer Cell DNA with Combinatorial Ligands$271,120
R01 · FY2004 · CA
THE PHARMACODYNAMICS OF GENES AND OLIGONUCLEOTIDES$934,303
P01 · FY2003 · GM
Targeting Cancer Cell DNA with Combinatorial Ligands$271,120
R01 · FY2003 · CA
MOLECULAR BASES OF CELL ADHESION$251,221
R01 · FY2003 · GM
Conference on Signaling Via Cell-Cell Interactions$13,000
R13 · FY2003 · CA
THE PHARMACODYNAMICS OF GENES AND OLIGONUCLEOTIDES$908,329
P01 · FY2002 · GM
Targeting Cancer Cell DNA with Combinatorial Ligands$271,120
R01 · FY2002 · CA
MOLECULAR BASES OF CELL ADHESION$251,221
R01 · FY2002 · GM
INTEGRIN SIGNALING IN THE VASCULAR SYSTEM$110,268
P01 · FY2002 · HL
TRANSPORT AND DELIVERY OF ANTISNESE OLIGONUCLEOTIDES$0
P01 · FY2002 · GM
THE PHARMACODYNAMICS OF GENES AND OLIGONUCLEOTIDES$951,726
P01 · FY2001 · GM
Targeting Cancer Cell DNA with Combinatorial Ligands$263,936
R01 · FY2001 · CA
MOLECULAR BASES OF CELL ADHESION$251,221
R01 · FY2001 · GM
INTEGRIN SIGNALING IN THE VASCULAR SYSTEM$110,268
P01 · FY2001 · HL
THE PHARMACODYNAMICS OF GENES AND OLIGONUCLEOTIDES$978,093
P01 · FY2000 · GM
INTEGRIN SIGNALING IN THE VASCULAR SYSTEM$259,933
P01 · FY2000 · HL
MOLECULAR BASES OF CELL ADHESION$251,221
R01 · FY2000 · GM
INTEGRIN MEDIATED GROWTH CONTROL IN COLON CARCINOMA$230,405
R01 · FY2000 · CA
TRANSPORT AND DELIVERY OF ANTISENSE OLIGONUCLEOTIDES$213,901
R01 · FY2000 · CA
TARGETING CANCER CELL DNA WITH COMBINATORIAL LIGANDS$180,184
R01 · FY2000 · CA